» Articles » PMID: 12971891

Parkinson's Disease: Mechanisms and Models

Overview
Journal Neuron
Publisher Cell Press
Specialty Neurology
Date 2003 Sep 16
PMID 12971891
Citations 2110
Authors
Affiliations
Soon will be listed here.
Abstract

Parkinson's disease (PD) results primarily from the death of dopaminergic neurons in the substantia nigra. Current PD medications treat symptoms; none halt or retard dopaminergic neuron degeneration. The main obstacle to developing neuroprotective therapies is a limited understanding of the key molecular events that provoke neurodegeneration. The discovery of PD genes has led to the hypothesis that misfolding of proteins and dysfunction of the ubiquitin-proteasome pathway are pivotal to PD pathogenesis. Previously implicated culprits in PD neurodegeneration, mitochondrial dysfunction and oxidative stress, may also act in part by causing the accumulation of misfolded proteins, in addition to producing other deleterious events in dopaminergic neurons. Neurotoxin-based models (particularly MPTP) have been important in elucidating the molecular cascade of cell death in dopaminergic neurons. PD models based on the manipulation of PD genes should prove valuable in elucidating important aspects of the disease, such as selective vulnerability of substantia nigra dopaminergic neurons to the degenerative process.

Citing Articles

LRRK2 in Drosophila Melanogaster Model: Insights into Cellular Dysfunction and Neuroinflammation in Parkinson's Disease.

Ciampelli C, Galleri G, Galioto M, Mereu P, Pirastru M, Bernardoni R Int J Mol Sci. 2025; 26(5).

PMID: 40076730 PMC: 11900240. DOI: 10.3390/ijms26052093.


Proceedings of the 12th annual deep brain stimulation think tank: cutting edge technology meets novel applications.

Martinez-Nunez A, Rozell C, Little S, Tan H, Schmidt S, Grill W Front Hum Neurosci. 2025; 19:1544994.

PMID: 40070487 PMC: 11893992. DOI: 10.3389/fnhum.2025.1544994.


Efficacy and safety of GLP-1 agonists in Parkinson's disease: a systematic review and meta-analysis of randomized controlled trials.

Messak M, Abdelmageed A, Senbel A, Khattab Y, Mandour Y, Shaker O Naunyn Schmiedebergs Arch Pharmacol. 2025; .

PMID: 40067438 DOI: 10.1007/s00210-025-03932-3.


Identifying network state-based Parkinson's disease subtypes using clustering and support vector machine models.

Nguchu B, Han Y, Wang Y, Shaw P Front Psychiatry. 2025; 16:1453852.

PMID: 40018689 PMC: 11865070. DOI: 10.3389/fpsyt.2025.1453852.


Motor and Non-Motor Effects of Acute MPTP in Adult Zebrafish: Insights into Parkinson's Disease.

Tagkalidou N, Stevanovic M, Romero-Alfano I, Elizalde-Velazquez G, Herrera-Vazquez S, Prats E Int J Mol Sci. 2025; 26(4).

PMID: 40004138 PMC: 11855887. DOI: 10.3390/ijms26041674.